No Data
No Data
H.C. Wainwright Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Maintains Target Price $21
H.C. Wainwright analyst Robert Burns maintains $Oric Pharmaceuticals(ORIC.US)$ with a buy rating, and maintains the target price at $21.According to TipRanks data, the analyst has a success rate of 28
Wedbush Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Maintains Target Price $20
Wedbush analyst David Nierengarten maintains $Oric Pharmaceuticals(ORIC.US)$ with a buy rating, and maintains the target price at $20.According to TipRanks data, the analyst has a success rate of 43.9
Analysts Are Bullish on Top Healthcare Stocks: Oric Pharmaceuticals (ORIC), Ufp Technologies (UFPT)
Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Applied Therapeutics (APLT) and Oric Pharmaceuticals (ORIC)
ORIC Pharmaceuticals (ORIC) Up on Collaboration With Bayer & JNJ
Oric Pharmaceuticals Price Target Maintained With a $21.00/Share by HC Wainwright & Co.
Oric Pharmaceuticals Price Target Maintained With a $21.00/Share by HC Wainwright & Co.
loading...
No Data